Exploring imaging techniques for diagnosing degenerative dementia

Study on Multimodal Imaging and Molecular Imaging Techniques in Degenerative Dementia

This study is trying to see if new imaging techniques can help doctors better diagnose and understand different types of dementia, including Alzheimer's, by tracking patients over time.

Quick facts

• Study type: Observational
• Enrollment: 1000 (estimated)
• Ages: 50 Years to 85 Years
• Sex: All
• Sponsor: Ruijin Hospital (Academic / other)
• Locations: 8 sites (Beijing, Beijing Municipality and 7 other locations)
• Trial ID: NCT06534658 on ClinicalTrials.gov

What this trial studies

This observational study aims to establish a longitudinal cohort of patients with Alzheimer's disease and other dementias by utilizing multimodal imaging and molecular imaging techniques. It will build a comprehensive database that includes neuroimaging, biological, and digital markers to investigate the mechanisms, diagnosis, evaluation, and prognosis of dementia. The study employs convolutional neural networks to analyze imaging characteristics and develop early prediction models for different dementia subtypes. Additionally, it will assess the diagnostic efficacy of new imaging probes through advanced imaging techniques and follow-up on patients with mild cognitive impairment.

Who should consider this trial

Good fit: Ideal candidates are individuals aged 50 to 85 who meet the diagnostic criteria for dementia or mild cognitive impairment.

Not a fit: Patients with other neurological or systemic diseases that could impair cognitive function may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to earlier and more accurate diagnoses of degenerative dementia, improving patient outcomes.

How similar studies have performed: Other studies utilizing multimodal imaging approaches have shown promise in improving diagnostic accuracy for dementia, indicating potential success for this study.

Eligibility criteria

Inclusion Criteria:

* Patients aged ≥50 and ≤85 years old, male or female;
* Meet the diagnostic criteria for dementia or MCI;
* Neuropsychological score: MMSE 15-28 points, CDR ≤ 1 point; ④ Patients and their families are informed and sign the informed consent form

Exclusion Criteria:

* The presence of other neurological diseases that may cause brain dysfunction (such as depression, brain tumors, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.);
* The presence of other systemic diseases that may cause cognitive impairment (such as liver dysfunction, renal dysfunction, thyroid dysfunction, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.);
* Suffering from a disease that makes it impossible to cooperate with cognitive examinations;
* The presence of contraindications to MRI;
* The presence of mental and neurological retardation;
* Refusing to draw blood;
* Refusing to sign the informed consent form.

Where this trial is running

Beijing, Beijing Municipality and 7 other locations

• Chinese People's Liberation Army General Hospital — Beijing, Beijing Municipality, China (Recruiting)
• First Affiliated Hospital of Zhejiang University School of Medicine — Hanzhong, Hangzhou, China (Recruiting)
• Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine — Cangzhou, Hebei, China (Recruiting)
• The Second Hospital of Hebei Medical University — Shijiazhuang, Hebei, China (Recruiting)
• Qilu Hospital of Shandong University, Qingdao Branch — Qingdao, Shandong, China (Recruiting)
• Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine — Shanghai, Shanghai Municipality, China (Recruiting)
• Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine — Shanghai, Shanghai Municipality, China (Recruiting)
• The First Affiliated Hospital of China Medical University — Shenyang, Shenyang, China (Recruiting)

Study contacts

• Principal investigator: Gang Wang, PhD. MD. — RenJi Hospital
• Study coordinator: Jintao Wang

Conditions Alzheimer Disease; Image; molecular imaging